ECM
ABMD

Everence Capital Management’s Abiomed Inc ABMD Stock Holding History

Everence Capital Management’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,040
Closed -$331K – 755
2021
Q1 		$331K Hold
1,040
– – 0.03% 518
2020
Q4 		$337K Buy
+1,040
New +$288K 0.03% 472

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Everence Capital Management's ABMD Position: Q2 2021 in Review

Everence Capital Management sold out of Abiomed Inc (ABMD) in Q2 2021, closing a stake of 1,040 shares — an estimated $331K sold.

Everence Capital Management first reported a position in ABMD in Q4 2020 and held it in 2 quarters. The position peaked at $337K in Q4 2020. 474 funds tracked by Wall St. Rank hold ABMD as of Q2 2021.

  • Everence Capital Management reported no remaining Abiomed Inc position as of Q2 2021 after selling out during the quarter.
  • Everence Capital Management sold 1,040 Abiomed Inc shares in Q2 2021, an estimated $331K.
  • Everence Capital Management first reported a position in Abiomed Inc in Q4 2020 and held it in 2 quarters.
  • Everence Capital Management's Abiomed Inc position peaked at $337K in Q4 2020.
  • 474 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2021.

Based on Everence Capital Management's 13F filing for Q2 2021, filed 12 Jul 2021.